In keeping with these results, upon lapatinib treatment, which targets both EGFR and HER2 receptors, it has been observed that HER2+ breast cancer cells are enriched of high membrane-Jagged1-expressing BCSCs, thus resulting in a higher mammosphere forming efficiency causing lapatinib resistance[108]. Here, ERBB2 is linked to breast carcinoma.